Stryker Misses Q1 on Cyber Disruption, Premium Valuation at Risk

What happened

Stryker reported Q1 earnings and revenue below consensus, citing a cyber incident that disrupted production and dented margins. The miss comes despite underlying demand strength across key segments, and the company had previously guided for tariff headwinds of $175-200M in 2025. Given the stock already trades at ~46x earnings, any operational stumble—whether from cyber, tariffs, or integration—exposes the rich multiple to compression. The cyber event underscores operational fragility in an otherwise high-quality franchise, and near-term visibility is reduced.

Implication

Stryker’s competitive advantages in robotics and vascular remain intact, and the cyber impact is likely transient. However, the premium valuation leaves no room for error, so any persistent operational issues could trigger material multiple de-rating. Longer-term buyers should wait for a more attractive entry point closer to DCF value (~$124).

Thesis delta

The cyber incident adds near-term operational risk that was not fully priced in, given Stryker’s rich valuation. While the underlying growth story is unchanged, the miss and disruption increase the probability of a short-term re-rating lower. We shift from a potential sell to a more cautious stance, reducing conviction in near-term upside.